Terns Pharma Q2 EPS $(0.25) Beats $(0.34) Estimate
Portfolio Pulse from Benzinga Newsdesk
Terns Pharma reported Q2 losses of $(0.25) per share, beating the analyst consensus estimate of $(0.34) by 26.47 percent. This is a 54.55 percent increase over losses of $(0.55) per share from the same period last year.
August 08, 2023 | 9:43 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Terns Pharma's Q2 earnings beat analyst estimates, showing a significant improvement over the same period last year.
Terns Pharma's Q2 earnings beat analyst estimates, which is generally a positive signal for investors. The significant improvement over the same period last year indicates that the company's financial performance is improving, which could lead to a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100